Replies to post #424118 on Anavex Life Sciences Corp (AVXL)

[kevindenver]

S1R as a therapeutic target is represented in a few of those companies is definitely worth a mention.

[Joseph_K]

I don't think the Parkinson's omission should bother you. The article is expressly about "Late-Stage Contenders." All the reviewed drugs (maybe I missed an exception, don't think so) have started or completed Phase 3 trials. For Parkinson's or PDD, there are no Anavex Phase 3s underway. I was glad to see blarcamesine on the list for AD.